<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326417</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0301</org_study_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>5U01HL069294-05</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT00326417</nct_id>
    <nct_alias>NCT00335608</nct_alias>
  </id_info>
  <brief_title>Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)</brief_title>
  <official_title>Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to continue to optimize conditioning regimens in
      high-risk patients with severe aplastic anemia transplanted with marrow from HLA-compatible
      unrelated donors. Specifically, the study will determine whether the addition of fludarabine
      to the conditioning regimen previously described by Deeg et al. will permit a reduction in
      the CY dose, to a point where sustained hematopoietic engraftment and survival are maintained
      (or improved), while the frequency of major regimen-related toxicity (RRT) and early deaths
      is reduced.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Aplastic anemia (AA) remains a life-threatening illness. Treatment options include supportive
      care (transfusions, growth factors, etc.), immunosuppression therapy and stem cell
      transplantation. Only the latter two have favorably impacted the natural history of the
      disease. The prognosis of AA patients, particularly severe aplastic anemia (SAA), as defined
      by Camitta et al., who fail to respond to immunosuppressive therapy (IS) or who relapse after
      an initial response to IS is poor. Although many of these patients can be supported in the
      short term with growth factors, transfusions and possibly rechallenged successfully with IS,
      the cumulative morbidity and mortality from infection, hemorrhage or transfusion-related
      complications is substantial.

      While allogeneic bone marrow transplantation is potentially curative in AA, no more than 25%
      of patients have a human leukocyte antigen (HLA)-identical sibling donor. Cyclophosphamide
      (CY)-antithymocyte globulin (ATG) has been recommended as the preparative regimen of choice
      in sibling donor transplants. Results of bone marrow transplantation from alternative donors,
      such as matched unrelated donors and mismatched related donors in AA patients who have failed
      IS, have largely been unsatisfactory. The cyclophosphamide-ATG conditioning regimen has
      proved inadequate in ensuring engraftment in allogeneic transplants from matched, unrelated
      donors for AA. This was the major reason why total body radiation (TBI) has been added to the
      conditioning regimen.

      Graft failure is a very serious and frequently life-threatening or fatal event following
      matched unrelated donor (MUD) allografts in aplastic anemia. It is an immunologically
      mediated event. Risk factors for graft failure include the use of HLA nonidentical or
      unrelated donors, a poor marrow nucleated cell dose as well as prolonged transfusional
      support prior to BMT (which increases the probability of patient sensitization to multiple
      antigens). While some patients may achieve autologous hematopoietic recovery, prolonged
      pancytopenia is common and infection-related morbidity and mortality are very substantial.
      Reconditioning for a second allograft from the same or a different donor is frequently not
      successful. While the addition of TBI and intensive pre-transplant conditioning has led to a
      sizable improvement in engraftment rates, this has come with a price, particularly in adult
      patients. Transplant-related toxicity has been a major and frequent problem.
      Radiation-induced pulmonary toxicity in particular has been common, usually in the form of
      diffuse alveolar damage or diffuse interstitial pneumonitis. In addition, Graft Versus Host
      Disease (GVHD)-related morbidity and mortality in these patients have also been substantial.

      DESIGN NARRATIVE:

      The study is a prospective Phase I/II dose optimization study. All patients are given a fixed
      dose of ATG (either thymoglobulin: 3 mg/kg IV daily x 3 or ATGAM 30 mg/kg IV daily x 3, on
      Days -4 to -2), Fludarabine (30 mg/m^2 IV daily x 4, on Days - 5 to -2), and TBI (200 cGy
      (centigray) from a linear accelerator at less than 20 cGy/min on Day -1). The starting CY
      dose will be 150 mg/kg (50 mg/kg intravenously daily, Days -4 to -2), and will be
      de-escalated depending on engraftment and toxicity. The Phase I portion of the trial (maximum
      of 24-27 patients) tests each of four dose levels of CY for adequate safety and graft
      retention. The Phase II portion of the trial refines the dose selection and allocates an
      additional 70 patients to the optimal dose, at which two-year post-transplant survival will
      be assessed. The combined enrollment in Phase I and II will total 94 patients.

      The study is a prospective single-arm Phase I/II dose-selection and evaluation study. The
      study will seek the optimal dose level of CY based on assessments of graft failure, toxicity
      and early death during 100 days of follow-up post-transplant. A brief synopsis is given
      below.

      Phase I - Test Each Dose for Adequate Safety and Graft Retention

        1. Proceed from the highest dose (150 mg/kg CY) to the lowest dose (0 mg/kg CY), treating a
           minimum of six patients at each dose.

        2. Evaluate the 100-Day outcomes for toxicity, death and graft failure on each patient
           enrolled at the current dose, or until stopping criteria are met.

        3. If there are three or more graft failures at the current dose, the current dose and all
           lower doses are closed to further enrollment.

        4. If there are five or more severe regimen-related toxicities and/or early deaths at the
           current dose, the current dose is closed to further enrollment, and the next lower dose
           is tested.

        5. Dose de-escalation ceases once all four doses are tested or closed to further
           enrollment.

      Phase II - Refine Dose Selection and Allocate Patients to the Optimal Dose

        1. Treat each newly enrolled patient at the most desirable of the dose levels remaining
           open to enrollment. This can involve de-escalation, escalation, or no change in dose.

        2. As each patient completes the observation period, evaluate the 100-Day outcomes for
           graft failure, toxicity and/or early death for this patient, or until stopping criteria
           are met.

        3. If there are excess (according to the criteria in Table 5.8) graft failures, that
           patient's dose and all lower doses are closed to further enrollment.

        4. If there are excess (according to the criteria in Table 5.8) toxicities and/or early
           deaths, that patient's dose is closed to further enrollment.

        5. Re-evaluate the desirability of the current dose level based on the 100-Day outcomes for
           toxicity and/or early death and graft failure.

        6. Repeat steps 1-5 until 54 patients are enrolled in Phase II, or all dose levels are
           closed to further enrollment.

      Dosage Levels for CY:

      3 Days (Day -4, -3, -2): Dose of 50 mg/kg/day; total dose of 150 mg/kg; dose level 3

      2 Days (Day -3, -2): Dose of 50 mg/kg/day; total dose of 100 mg/kg; dose level 2

      1 Day (Day -2): Dose of 50 mg/kg/day; total dose of 50 mg/kg; dose level 1

      0 Days (None): No dose; no total dose; dose level 0

      There may be wait periods between enrollment of successive patients and/or cohorts for
      endpoint assessment. Under these circumstances, the final decision about waiting versus
      treating the patient off study will be made at the local transplant center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Day 100</time_frame>
    <description>DFS includes graft failure, regimen-related toxicity (RRT), and early death. Graft Failure is defined by lack of neutrophil engraftment (ANC less than 0.5 x 10^9/L for 3 consecutive days on different days). Major RRT is defined as severity of grade 4 in any organ system or grade 3 for pulmonary, cardiac, renal, oral mucosal or hepatic. Early death is defined as death prior to Day 100 post-transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Graft Failure</measure>
    <time_frame>Day 365</time_frame>
    <description>Primary and secondary graft failure are included, secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in the ANC to less than 0.5 x 10^9/L for three consecutive measurements on different days, unresponsive to growth factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft vs Host Disease (GVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>All GVHD grades 2-4 will be graded according to the BMT CTN Manual of Procedures (MOP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Day 365</time_frame>
    <description>Chronic GVHD is scored according to the BMT CTN MOP. The first day of chronic GVHD onset will be used to calculate cumulative incidence curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Day 365</time_frame>
    <description>OS is defined as alive at 1 year, the event is death from any cause. Patients alive at the time of last observation, for statistical purposes, will have a survival time which is censored.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Anemia, Aplastic</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine only (no Cyclophosphamide administered)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Doses of 30 mg/m^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)</description>
    <arm_group_label>Cyclophosphamide 150mg</arm_group_label>
    <arm_group_label>Cyclophosphamide 100mg</arm_group_label>
    <arm_group_label>Cyclophosphamide 50mg</arm_group_label>
    <arm_group_label>Fludarabine</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 150mg</intervention_name>
    <description>A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)</description>
    <arm_group_label>Cyclophosphamide 150mg</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 100mg</intervention_name>
    <description>A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)</description>
    <arm_group_label>Cyclophosphamide 100mg</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 50mg</intervention_name>
    <description>A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2</description>
    <arm_group_label>Cyclophosphamide 50mg</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients up to 65 years of age at time of registration with a diagnosis of SAA; SAA is
             defined as follows:

               1. Bone marrow cellularity less than 25% or marrow cellularity less than 50% but
                  with less than 30% residual hematopoietic cells

               2. Two out of three of the following (in peripheral blood): neutrophils less than
                  0.5 x 10^9/L; platelets less than 20 x 10^9/L; reticulocytes less than 20 x
                  10^9/L

          -  Patient must have an available unrelated donor with a 7/8 or 8/8 match for HLA-A, B,
             C, and DRB1 antigen; typing is by DNA techniques: intermediate resolution for A, B,
             and C, and high resolution for DRB1; HLA-DQ typing is recommended but will not count
             in the match

          -  Patient and/or legal guardian able to provide signed informed consent

          -  Matched unrelated donor must consent to provide a marrow allograft

          -  Patients with adequate organ function as measured by:

               1. Cardiac: left ventricular ejection fraction at rest must be greater than 40% or
                  shortening fraction greater than 20%

               2. Hepatic: serum bilirubin less than 2x upper limit of normal for age as per local
                  laboratory) (with the exception of isolated hyperbilirubinemia due to Gilbert's
                  syndrome), alanine transaminase (ALT) and aspartate transaminase (AST) less than
                  4x upper limit of normal for age (as per local laboratory)

               3. Renal: serum creatinine less than 2x upper limit of normal for age (as per local
                  laboratory)

               4. Pulmonary: Forced expiratory volume in 1 second (FEV1), forced vital capacity
                  (FVC), and carbon monoxide diffusing capacity (DLCO) (corrected for Hb) greater
                  than 50% predicted; for patients in which pulse oxymetry is performed, O2
                  saturation greater than 92%

          -  Diagnosis of Fanconi anemia must be excluded in patients younger than 18 years of age
             by diepoxybutane testing on peripheral blood or comparable testing on marrow.

        Exclusion Criteria:

          -  Clonal cytogenetic abnormalities associated with myelodysplastic syndrome (MDS) or
             acute myeloid leukemia (AML) on marrow examination

          -  Diagnosis of other &quot;congenital&quot; aplastic anemias such as: Diamond-Blackfan;
             Shwachman-Diamond; congenital amegakaryocytosis

          -  Symptomatic or uncontrolled cardiac failure or coronary artery disease

          -  Karnofsky performance status less than 60% or Lansky less than 40% for patients
             younger than 16 years old

          -  Uncontrolled bacterial, viral or fungal infections (currently taking medication and
             progression of clinical symptoms)

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Pregnant (positive total HCG) or breastfeeding

          -  Presence of large accumulation of ascites or pleural effusions, which would be a
             contraindication to the administration of methotrexate for GVHD prophylaxis

          -  Known severe or life-threatening allergy or intolerance to ATG or cyclosporine/
             tacrolimus

          -  Planned administration of alemtuzumab (Campath-1H) or other investigational agents as
             alternative agent for GVHD prophylaxis

          -  Concomitant enrollment in a Phase I study

          -  Positive patient anti-donor lymphocyte crossmatch in HLA-A or B mismatched
             transplants; the definition of match is in Section 2.2.1; the crossmatch would only
             apply to mismatches at HLA-A or B, not DRB1 or HLA-C

          -  Prior allogeneic marrow or stem cell transplantation

          -  Patients with prior malignancies except resected basal cell carcinoma or treated
             carcinoma in-situ; cancer treated with curative intent less than 5 years previously
             will not be allowed unless approved by the Medical Monitor or Protocol Chair; cancer
             treated with curative intent more than 5 years previously will be allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMT Program at Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI/Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, MCV Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <reference>
    <citation>Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011 Mar;17(3):291-9. doi: 10.1016/j.bbmt.2010.10.028. Epub 2010 Oct 27.</citation>
    <PMID>21034841</PMID>
  </reference>
  <results_reference>
    <citation>Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep;2(9):e367-75. doi: 10.1016/S2352-3026(15)00147-7. Epub 2015 Sep 2.</citation>
    <PMID>26685770</PMID>
  </results_reference>
  <results_reference>
    <citation>Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11. doi: 10.1016/j.bbmt.2012.04.014. Epub 2012 Apr 27.</citation>
    <PMID>22546497</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2006</study_first_submitted>
  <study_first_submitted_qc>May 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2006</study_first_posted>
  <results_first_submitted>August 10, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2016</results_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Aplastic Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings will be published in a manuscript.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from February 2006 to August 2007 for Phase I of the trial. Phase II opened in November 2007 and closed to accrual on December 2, 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyclophosphamide 150mg</title>
          <description>Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="P2">
          <title>Cyclophosphamide 100mg</title>
          <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="P3">
          <title>Cyclophosphamide 50mg</title>
          <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="P4">
          <title>Fludarabine</title>
          <description>Fludarabine only (no Cyclophosphamide administered)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase I</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase II</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Dose level was closed for excessive toxicity after 8 patients in Phase II accrued.</participants>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="0">Arm was closed to accrual after 3 patients experienced graft failure.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Arm Closed</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclophosphamide 100mg</title>
          <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="B2">
          <title>Cyclophosphamide 50mg</title>
          <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" lower_limit="1.9" upper_limit="63.3"/>
                    <measurement group_id="B2" value="24.5" lower_limit="0.5" upper_limit="65.9"/>
                    <measurement group_id="B3" value="20.6" lower_limit="0.5" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recipient Cytomegalovirus Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Score</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunosuppressive therapy prior to transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor-recipient HLA match</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HLA-A, -B, -C,-DRB1 matched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single HLA-locus mismatch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of anti-thymocyte globulin administered</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Rabbit-derived</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Horse-derived</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>DFS includes graft failure, regimen-related toxicity (RRT), and early death. Graft Failure is defined by lack of neutrophil engraftment (ANC less than 0.5 x 10^9/L for 3 consecutive days on different days). Major RRT is defined as severity of grade 4 in any organ system or grade 3 for pulmonary, cardiac, renal, oral mucosal or hepatic. Early death is defined as death prior to Day 100 post-transplant.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 100mg</title>
            <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 50mg</title>
            <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>DFS includes graft failure, regimen-related toxicity (RRT), and early death. Graft Failure is defined by lack of neutrophil engraftment (ANC less than 0.5 x 10^9/L for 3 consecutive days on different days). Major RRT is defined as severity of grade 4 in any organ system or grade 3 for pulmonary, cardiac, renal, oral mucosal or hepatic. Early death is defined as death prior to Day 100 post-transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Graft Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major RRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive and engrafted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Graft Failure</title>
        <description>Primary and secondary graft failure are included, secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in the ANC to less than 0.5 x 10^9/L for three consecutive measurements on different days, unresponsive to growth factor.</description>
        <time_frame>Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 100mg</title>
            <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 50mg</title>
            <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Graft Failure</title>
          <description>Primary and secondary graft failure are included, secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in the ANC to less than 0.5 x 10^9/L for three consecutive measurements on different days, unresponsive to growth factor.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft vs Host Disease (GVHD)</title>
        <description>All GVHD grades 2-4 will be graded according to the BMT CTN Manual of Procedures (MOP)</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 100mg</title>
            <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 50mg</title>
            <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft vs Host Disease (GVHD)</title>
          <description>All GVHD grades 2-4 will be graded according to the BMT CTN Manual of Procedures (MOP)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="13" upper_limit="40.6"/>
                    <measurement group_id="O2" value="23.7" lower_limit="10" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic GVHD</title>
        <description>Chronic GVHD is scored according to the BMT CTN MOP. The first day of chronic GVHD onset will be used to calculate cumulative incidence curves.</description>
        <time_frame>Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 100mg</title>
            <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 50mg</title>
            <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic GVHD</title>
          <description>Chronic GVHD is scored according to the BMT CTN MOP. The first day of chronic GVHD onset will be used to calculate cumulative incidence curves.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="18.1" upper_limit="46.2"/>
                    <measurement group_id="O2" value="22.5" lower_limit="10.3" upper_limit="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as alive at 1 year, the event is death from any cause. Patients alive at the time of last observation, for statistical purposes, will have a survival time which is censored.</description>
        <time_frame>Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclophosphamide 100mg</title>
            <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
          </group>
          <group group_id="O2">
            <title>Cyclophosphamide 50mg</title>
            <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as alive at 1 year, the event is death from any cause. Patients alive at the time of last observation, for statistical purposes, will have a survival time which is censored.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="64.8" upper_limit="89.7"/>
                    <measurement group_id="O2" value="97.4" lower_limit="82.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year post-transplant</time_frame>
      <desc>Serious Adverse Events (AE) are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected grades 3-5 adverse events were required to be reported through the AE system per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclophosphamide 150mg</title>
          <description>Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="E2">
          <title>Cyclophosphamide 100mg</title>
          <description>Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="E3">
          <title>Cyclophosphamide 50mg</title>
          <description>Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)</description>
        </group>
        <group group_id="E4">
          <title>Fludarabine</title>
          <description>Fludarabine only (no Cyclophosphamide administered)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The Emmes Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

